UCB S.A. 60 Allée de la Recherche, B-1070 Brussels (Belgium)

Press Release

UCB REPORTS POSITIVE OPINION FROM EMEA FOR PAEDIATRIC INDICATION FOR KEPPRA®

Brussels (Belgium) August 1st, 2005: UCB today reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion, recommending approval of Keppra® as adjunctive therapy in the treatment of partial-onset seizures, with or without secondary generalisation, in children four years of age and older with epilepsy. "The CHMP positive recommendation is an important milestone towards making Keppra® available to European children with epilepsy", commented Peter Verdru MD, Vice President Clinical Research, UCB. The CHMP's opinion is now forwarded to the European Commission for review and final decision, which is expected within 90 days. In June 2005, the US Food and Drug Administration (FDA) approved the pediatric indication for Keppra® under priority review.

About UCB

UCB - www.ucb-group.com - is a global biopharmaceutical leader with headquarters in Brussels, Belgium, specializing in the fields of central nervous system disorders, allergy and respiratory diseases, immune and inflammatory disorders, as well as oncology. UCB key products are Keppra® (antiepileptic), Xyzal® and Zyrtec® (antiallergics), Nootropil® (cerebral function regulator), Tussionex™ (antitussive) and Metadate™ / Equasym XL™ (attention-deficit/hyperactivity disorder). UCB employs over 8,500 people operating in over 40 countries. UCB is listed on Euronext Brussels with a market capitalization of approximately € 5.8 billion.

For further enquiries, please contact

Jean-Christophe Donck

Vice President Corporate Communications and Investor Relations

+32 2 559 9588

jc.donck@ucb-group.com